Sygnature Discovery, a drug discovery and preclinical services company, is expanding its operations with the opening of its first U.S. office in Harvard Square, Cambridge, MA. 

Earlier in 2018, Sygnature appointed its first U.S. based business development representative to build on its North American presence. The U.S. is Sygnature Discovery’s largest market and with the new office the company is able to strengthen its commitment to its U.S. customer base.

Sygnature Discovery’s chief executive officer, Dr. Simon Hirst said, “Clients from all over the world come to Sygnature because we are able to offer not only a high-quality, fully-integrated drug discovery and pre-clinical service, but we also have the flexibility to provide stand-alone medicinal chemistry, in vitro biology, computational chemistry, DMPK and pre-clinical experimental services through our subsidiary company, RenaSci. As a business we have seen significant growth outside of the UK in recent years; particularly in the USA. The Boston and Cambridge area is a key life sciences hub and our office location there will ensure that we are closer to many of our key customers, both current and potential.”

Sygnature also recently added a new DMPK facility in Cheshire, UK.